{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:53Z","timestamp":1787243393531,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04517-x","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:48:15Z","timestamp":1786063695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic utility of the Charlson comorbidity index in pancreatic cancer: a systematic review and meta\u2011analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"3","key":"4517_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4517_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"4517_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00018-023-04855-z","volume":"80","author":"AC Lilly","year":"2023","unstructured":"Lilly AC, Astsaturov I, Golemis EA. Intrapancreatic fat, pancreatitis, and pancreatic cancer. Cell Mol Life Sci. 2023;80(8):206. https:\/\/doi.org\/10.1007\/s00018-023-04855-z.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4517_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2022;91(1):8\u201335. https:\/\/doi.org\/10.1159\/000521288.","journal-title":"Psychother Psychosom"},{"issue":"4","key":"4517_CR5","first-page":"188","volume":"12","author":"WP Glasheen","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. Am Health Drug Benefits. 2019;12(4):188\u201397.","journal-title":"Am Health Drug Benefits"},{"issue":"6suppl","key":"4517_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/jco.2013.31.6_suppl.242","volume":"31","author":"DS Cross","year":"2013","unstructured":"Cross DS, Islam R, Mullins CD, Hussain A, Jacobson C, Foth W, et al. The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. J Clin Oncol. 2013;31(6suppl):242. https:\/\/doi.org\/10.1200\/jco.2013.31.6_suppl.242.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4517_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"4517_CR8","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1245\/s10434-025-17467-7","volume":"32","author":"A Khalid","year":"2025","unstructured":"Khalid A, Shah M, Fazal AA, Newman E, DePeralta D, Gholami S, et al. Standard-Adherent Surgery and Guideline-Based Therapy in Pancreatic Cancer: A Multicenter Analysis. Ann Surg Oncol. 2025;32(9):6519\u201330. https:\/\/doi.org\/10.1245\/s10434-025-17467-7.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4517_CR9","doi-asserted-by":"publisher","first-page":"e13219","DOI":"10.1111\/ecc.13219","volume":"29","author":"K Bagni","year":"2020","unstructured":"Bagni K, Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Hansen CP, et al. Prognostic impact of Charlson\u2019s Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. Eur J Cancer Care (Engl). 2020;29(3):e13219. https:\/\/doi.org\/10.1111\/ecc.13219.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"4517_CR10","doi-asserted-by":"publisher","first-page":"1487318","DOI":"10.3389\/fimmu.2025.1487318","volume":"16","author":"N Zhang","year":"2025","unstructured":"Zhang N, Chen S, Shi Y, Wang Z, Jia R, Dai G. Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy. Front Immunol. 2025;16:1487318. https:\/\/doi.org\/10.3389\/fimmu.2025.1487318.","journal-title":"Front Immunol"},{"key":"4517_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"4517_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-019-6255-3","volume":"19","author":"HM Park","year":"2019","unstructured":"Park HM, Park SJ, Han SS, Kim SH. Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer. BMC Cancer. 2019;19(1):1090. https:\/\/doi.org\/10.1186\/s12885-019-6255-3.","journal-title":"BMC Cancer"},{"issue":"1","key":"4517_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12029-025-01188-x","volume":"56","author":"A Sridharan","year":"2025","unstructured":"Sridharan A, Dotan E, Dorta M, Vemula N, Handorf E, Deng M, et al. Racial\/Ethnic Differences and Effects of Clinical\/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. J Gastrointest Cancer. 2025;56(1):67. https:\/\/doi.org\/10.1007\/s12029-025-01188-x.","journal-title":"J Gastrointest Cancer"},{"issue":"12","key":"4517_CR14","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1002\/cam4.1841","volume":"7","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O, Xu Y, Tang PA, Lee-Ying RM, Cheung WY. A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. Cancer Med. 2018;7(12):6385\u201392. https:\/\/doi.org\/10.1002\/cam4.1841.","journal-title":"Cancer Med"},{"issue":"7","key":"4517_CR15","doi-asserted-by":"publisher","first-page":"e0199909","DOI":"10.1371\/journal.pone.0199909","volume":"13","author":"S Bhandari","year":"2018","unstructured":"Bhandari S, Abdul MKM, Hollabaugh W, Sharma K, Evans DB, Guda N. Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions. PLoS ONE. 2018;13(7):e0199909. https:\/\/doi.org\/10.1371\/journal.pone.0199909.","journal-title":"PLoS ONE"},{"issue":"11","key":"4517_CR16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1055\/a-1784-1661","volume":"54","author":"D King","year":"2022","unstructured":"King D, Kamran U, Dosanjh A, Coupland B, Mytton J, Leeds JS, et al. Rate of pancreatic cancer following a negative endoscopic ultrasound and associated factors. Endoscopy. 2022;54(11):1053\u201361. https:\/\/doi.org\/10.1055\/a-1784-1661.","journal-title":"Endoscopy"},{"key":"4517_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijsu.2017.01.115","volume":"39","author":"T Asano","year":"2017","unstructured":"Asano T, Yamada S, Fujii T, Yabusaki N, Nakayama G, Sugimoto H, et al. The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. Int J Surg. 2017;39:169\u201375. https:\/\/doi.org\/10.1016\/j.ijsu.2017.01.115.","journal-title":"Int J Surg"},{"issue":"10","key":"4517_CR18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ejca.2011.10.035","volume":"48","author":"MM Vickers","year":"2012","unstructured":"Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O\u2019Callaghan CJ, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012;48(10):1434\u201342. https:\/\/doi.org\/10.1016\/j.ejca.2011.10.035.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4517_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.critrevonc.2010.05.007","volume":"78","author":"Y Nakai","year":"2011","unstructured":"Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Kogure H, et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78(3):252\u20139. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.05.007.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"4517_CR20","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1245\/s10434-016-5456-0","volume":"23","author":"JC King","year":"2016","unstructured":"King JC, Zenati M, Steve J, Winters SB, Bartlett DL, Zureikat AH, et al. Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Ann Surg Oncol. 2016;23(13):4149\u201355. https:\/\/doi.org\/10.1245\/s10434-016-5456-0.","journal-title":"Ann Surg Oncol"},{"issue":"45","key":"4517_CR21","doi-asserted-by":"publisher","first-page":"79453","DOI":"10.18632\/oncotarget.18401","volume":"8","author":"Y Tian","year":"2017","unstructured":"Tian Y, Jian Z, Xu B, Liu H. Age-adjusted Charlson comorbidity index score as predictor of survival of patients with digestive system cancer who have undergone surgical resection. Oncotarget. 2017;8(45):79453\u201361. https:\/\/doi.org\/10.18632\/oncotarget.18401.","journal-title":"Oncotarget"},{"key":"4517_CR22","doi-asserted-by":"publisher","first-page":"102169","DOI":"10.1016\/j.suronc.2024.102169","volume":"58","author":"A Hamadalnile","year":"2025","unstructured":"Hamadalnile A, Mariathasan M, Riad M, Patel AG, Atkinson S, Prachalias AA, et al. Delayed surgery during the Covid-19 pandemic did not affect long-term outcomes of pancreatic adenocarcinoma. Surg Oncol. 2025;58:102169. https:\/\/doi.org\/10.1016\/j.suronc.2024.102169.","journal-title":"Surg Oncol"},{"issue":"1\u20132","key":"4517_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00508-013-0453-9","volume":"126","author":"FT Kos","year":"2014","unstructured":"Kos FT, Yazici O, Civelek B, Seker M, Arik Z, Aksoy S, et al. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using Charlson Comorbidity Index and Cumulative Illness Rating Scale. Wien Klin Wochenschr. 2014;126(1\u20132):36\u201341. https:\/\/doi.org\/10.1007\/s00508-013-0453-9.","journal-title":"Wien Klin Wochenschr"},{"issue":"23","key":"4517_CR24","doi-asserted-by":"publisher","first-page":"37646","DOI":"10.18632\/oncotarget.16841","volume":"8","author":"L Cai","year":"2017","unstructured":"Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, et al. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(23):37646\u201356. https:\/\/doi.org\/10.18632\/oncotarget.16841.","journal-title":"Oncotarget"},{"issue":"3","key":"4517_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ijc.34271","volume":"152","author":"N Marschner","year":"2023","unstructured":"Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, et al. FOLFIRINOX or gemcitabine\/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world. Int J Cancer. 2023;152(3):458\u201369. https:\/\/doi.org\/10.1002\/ijc.34271.","journal-title":"Int J Cancer"},{"key":"4517_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.sopen.2023.02.001","volume":"12","author":"BD Powers","year":"2023","unstructured":"Powers BD, Allenson K, Perone JA, Thompson Z, Boulware D, Denbo JW, et al. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Surg Open Sci. 2023;12:14\u201321. https:\/\/doi.org\/10.1016\/j.sopen.2023.02.001.","journal-title":"Surg Open Sci"},{"issue":"10","key":"4517_CR27","doi-asserted-by":"publisher","first-page":"e37440","DOI":"10.1097\/md.0000000000037440","volume":"103","author":"Q Man","year":"2024","unstructured":"Man Q, Pang H, Liang Y, Chang S, Wang J, Gao S. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study. Med (Baltim). 2024;103(10):e37440. https:\/\/doi.org\/10.1097\/md.0000000000037440.","journal-title":"Med (Baltim)"},{"issue":"4","key":"4517_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.hpb.2021.09.004","volume":"24","author":"LA Daamen","year":"2022","unstructured":"Daamen LA, Dorland G, Brada LJH, Groot VP, van Oosten AF, Besselink MG, et al. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. HPB (Oxford). 2022;24(4):535\u201346. https:\/\/doi.org\/10.1016\/j.hpb.2021.09.004.","journal-title":"HPB (Oxford)"},{"issue":"Supplement","key":"4517_CR29","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.4103\/jcrt.JCRT_440_18","volume":"16","author":"T Aoyama","year":"2020","unstructured":"Aoyama T, Yamamoto N, Kamiya M, Murakawa M, Tamagawa H, Sawazaki S, et al. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy. J Cancer Res Ther. 2020;16(Supplement):S116\u201321. https:\/\/doi.org\/10.4103\/jcrt.JCRT_440_18.","journal-title":"J Cancer Res Ther"},{"issue":"21","key":"4517_CR30","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1002\/cncr.30199","volume":"122","author":"S Marmor","year":"2016","unstructured":"Marmor S, Burke EE, Virnig BA, Jensen EH, Tuttle TM. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Cancer. 2016;122(21):3378\u201385. https:\/\/doi.org\/10.1002\/cncr.30199.","journal-title":"Cancer"},{"issue":"6","key":"4517_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.surg.2015.06.017","volume":"158","author":"JT Miura","year":"2015","unstructured":"Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, et al. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery. 2015;158(6):1545\u201355. https:\/\/doi.org\/10.1016\/j.surg.2015.06.017.","journal-title":"Surgery"},{"issue":"12","key":"4517_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1159\/000480016","volume":"40","author":"G Chakupurakal","year":"2017","unstructured":"Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R. Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. Oncol Res Treat. 2017;40(12):784\u20138. https:\/\/doi.org\/10.1159\/000480016.","journal-title":"Oncol Res Treat"},{"key":"4517_CR33","doi-asserted-by":"publisher","unstructured":"Huang BZ, Chang JI, Li E, Xiang AH, Wu BU. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2017;109(5). https:\/\/doi.org\/10.1093\/jnci\/djw275.","DOI":"10.1093\/jnci\/djw275"},{"issue":"2","key":"4517_CR34","doi-asserted-by":"publisher","first-page":"e0148076","DOI":"10.1371\/journal.pone.0148076","volume":"11","author":"CM Chang","year":"2016","unstructured":"Chang CM, Yin WY, Wei CK, Wu CC, Su YC, Yu CH, et al. Adjusted Age-Adjusted Charlson Comorbidity Index Score as a Risk Measure of Perioperative Mortality before Cancer Surgery. PLoS ONE. 2016;11(2):e0148076. https:\/\/doi.org\/10.1371\/journal.pone.0148076.","journal-title":"PLoS ONE"},{"issue":"5","key":"4517_CR35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ejso.2018.01.095","volume":"44","author":"D Wagner","year":"2018","unstructured":"Wagner D, Marsoner K, Tomberger A, Haybaeck J, Haas J, Werkgartner G, et al. Low skeletal muscle mass outperforms the Charlson Comorbidity Index in risk prediction in patients undergoing pancreatic resections. Eur J Surg Oncol. 2018;44(5):658\u201363. https:\/\/doi.org\/10.1016\/j.ejso.2018.01.095.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"4517_CR36","doi-asserted-by":"publisher","first-page":"E1731","DOI":"10.1055\/a-1534-2558","volume":"9","author":"U Kamran","year":"2021","unstructured":"Kamran U, King D, Dosanjh A, Coupland B, Leeds J, Nayar M, et al. Pancreaticobiliary endoscopic ultrasound in England 2007 to 2016: Changing practice and outcomes. Endosc Int Open. 2021;9(11):E1731\u20139. https:\/\/doi.org\/10.1055\/a-1534-2558.","journal-title":"Endosc Int Open"},{"issue":"1","key":"4517_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.hpb.2024.10.011","volume":"27","author":"U Marchese","year":"2025","unstructured":"Marchese U, Lenne X, Naveendran G, Tzedakis S, Gaillard M, Richa Y, et al. Nationwide analysis of one-year mortality following pancreatectomy in 17,183 patients with pancreatic cancer. HPB (Oxford). 2025;27(1):123\u20139. https:\/\/doi.org\/10.1016\/j.hpb.2024.10.011.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"4517_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2\u201310. https:\/\/doi.org\/10.1111\/jebm.12141.","journal-title":"J Evid Based Med"},{"issue":"11","key":"4517_CR39","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"10","key":"4517_CR40","doi-asserted-by":"publisher","first-page":"e94099","DOI":"10.7759\/cureus.94099","volume":"17","author":"R Ohta","year":"2025","unstructured":"Ohta R, Tanaka Y, Tanaka K, Hayashi H. Impact of Comorbidity Burden on Clinical Outcomes in Older Adults With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Cureus. 2025;17(10):e94099. https:\/\/doi.org\/10.7759\/cureus.94099.","journal-title":"Cureus"},{"issue":"3","key":"4517_CR41","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.euf.2021.04.020","volume":"8","author":"M Lardas","year":"2022","unstructured":"Lardas M, Grivas N, Debray TPA, Zattoni F, Berridge C, Cumberbatch M, et al. Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2022;8(3):674\u201389. https:\/\/doi.org\/10.1016\/j.euf.2021.04.020.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"4517_CR42","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.ijrobp.2025.07.1431","volume":"123","author":"LL Thompson","year":"2025","unstructured":"Thompson LL, Amin PM, Shah S, Lipson SM, Yoon J, Lee G, et al. Associations Between G8 Geriatric Screening Score, Charlson Comorbidity Index, AI-Based Age Phenotype, and Overall Survival in Older Adults With Stage I-II Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2025;123(5):1295\u2013305. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.07.1431.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"4517_CR43","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1158\/0008-5472.Can-22-2679","volume":"83","author":"R Zhang","year":"2023","unstructured":"Zhang R, Peng X, Du JX, Boohaker R, Estevao IL, Grajeda BI, et al. Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis. Cancer Res. 2023;83(22):3739\u201352. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-2679.","journal-title":"Cancer Res"},{"issue":"5","key":"4517_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2217\/imt-2023-0270","volume":"16","author":"\u0130D Onur","year":"2024","unstructured":"Onur \u0130D, Mutlu E, Sertesen E, \u00d6nder T, Duran AO, \u0130nan\u00e7 M. Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events. Immunotherapy. 2024;16(5):295\u2013303. https:\/\/doi.org\/10.2217\/imt-2023-0270.","journal-title":"Immunotherapy"},{"issue":"16suppl","key":"4517_CR45","doi-asserted-by":"publisher","first-page":"12061","DOI":"10.1200\/JCO.2023.41.16_suppl.12061","volume":"41","author":"AT Faucheux","year":"2023","unstructured":"Faucheux AT, Klepin HD, Levine BJ, Quattlebaum AM, Bloomer CH, Khoury LM, et al. Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy. J Clin Oncol. 2023;41(16suppl):12061. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.12061.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04517-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:18:55Z","timestamp":1787242735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04517-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4517"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04517-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"341"}}